Accessing KRASG12C: A New Anticancer Approach
  • CME

Explore new anticancer strategies targeting KRASG12C in solid tumors in this expert-authored online activity with downloadable slides.
Marwan Fakih, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: October 29, 2020 Expiration: October 28, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the relevance of KRAS in oncogenesis and the prevalence of KRAS p.G12C in patients with solid tumors

  • Assess available evidence on the safety and efficacy of KRASG12C inhibitors in lung cancer and across multiple tumor types

  • Test patients with solid tumors for the KRAS p.G12C mutation

  • Refer eligible patients to clinical trials of novel agents which target KRASG12C in solid tumors


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Marwan Fakih, MD

Section Head,
Gastrointestinal Oncology
Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California

Marwan Fakih, MD, has disclosed that he has received fees for non-CME/CE services and funds for research support from Amgen.


Colleen Heffner, PharmD
Colleen Heffner, PharmD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen M Rosenthal, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has received salary from and holds ownership interests with AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare clinicians who care for patients with cancer.


The goal of this activity is to improve learners’ competence in applying the latest practice-changing data in the treatment of patients with solid tumors and the KRAS p.G12C mutation.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 29, 2020, through October 28, 2021:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 22, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 21, 2021

Downloadable slideset reviewing the latest therapeutic approaches for pancreatic cancer harboring BRCA mutations, from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Released: January 21, 2021

Downloadable CCO resource summarizing best practices for detection of RET gene alterations in lung and thyroid tumors

Released: January 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.